SCHEMBL2360271

SCHEMBL2360271

O=C1c2[nH]c3ccc(Br)cc3c2CCC1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
LMNA P02545 3/20 0.59
ALDH1A1 P00352 2/20 0.59
MAPK1 P28482 2/20 0.59
SIRT1 Q96EB6 1/20 0.48
CCNB2 O95067 10/20 0.48
CDK1 P06493 10/20 0.48
CCNB1 P14635 10/20 0.48
CCNB3 Q8WWL7 10/20 0.48
GSK3B P49841 9/20 0.47
CDK5 Q00535 7/20 0.47
CDK5R1 Q15078 7/20 0.47
HSD17B10 Q99714 2/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 2/20 0.45
ABL1 P00519 2/20 0.45
LCK P06239 2/20 0.45
FYN P06241 2/20 0.45
PIM1 P11309 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20602347 0.84 MAPT (0.58) MAPTLMNAALDH1A1MAPK1SIRT1
SCHEMBL20602696 0.84 LMNA (0.58) MAPTLMNAALDH1A1MAPK1SIRT1
SCHEMBL2361017 0.81 MAPK10 (0.50) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL4160282 0.77 LMNA (0.82) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL2360729 0.75 LMNA (1.00) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL4156981 0.75 LMNA (0.94) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL31721163 0.75 LMNA (1.00) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL29855719 0.74 MAPT (0.69) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL5263677 0.74 MAPT (0.69) MAPTLMNAALDH1A1MAPK1CCNB2
SCHEMBL2359992 0.70 AR (0.42) LMNAKDM4ECHEK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
EP-2531029-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2012-12-12 EP disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121285-A1 Selective androgen receptor modulators AR, SHBG, FSHR MAPT 2267/4885LMNA 1424/4885ALDH1A1 1511/4885
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, FSHR MAPT 2263/4885LMNA 1414/4885ALDH1A1 1542/4885
US-20130041007-A1 Selective Androgen Receptor Modulators AR, SHBG, GPR119 MAPT 2494/4885LMNA 1447/4885ALDH1A1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.